Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**maduramycin + nicarbazin** is a combination anticoccidial drug used primarily in poultry (broiler chickens) for preventing and controlling coccidiosis caused by various *Eimeria* species (including *E. acervulina*, *E. tenella*, *E. necatrix*, *E. maxima*, *E. brunetti*, and *E. mivati*)[1][2][3][5]. Maduramycin is an ionophore that acts by selectively increasing the transport of monovalent cations (sodium and potassium) through the cell membrane of *Eimeria*, leading to cell swelling and membrane destruction[1][2]. Nicarbazin is a synthetic, non-ionophore anticoccidial agent—specifically, a complex of 4,4'-dinitro-diphenyl-urea (DNC) and 2-hydroxy-4,6-dimethyl-pyrimidin (HDP)—that inhibits energy metabolism in the parasite[1][3]. The combination offers synergistic efficacy and helps to delay resistance development in target parasites[1][5][7]. The drugs act within the gastrointestinal tract and are excreted mostly unchanged in feces[1][3]. The product is supplied largely as a feed premix and is classified as low toxicity for poultry but is toxic to horses[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on maduramycin + nicarbazin.